Marathon Petroleum Corp vs Tempus AI — how do they compare? Marathon Petroleum Corp trades at $400.63 (market cap $111.70B), while Tempus AI trades at $61.18 (market cap $11.67B). The key difference: Marathon Petroleum Corp is far larger — about 9.6× Tempus AI's market cap, and Marathon Petroleum Corp pays a 1.01% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MPC | TEM | |
|---|---|---|
Market Cap | $111.70B | $11.67B |
Sector | Energy | Broad Market / Factor |
52-Week High | $399.44 | $103.25 |
52-Week Low | $162.63 | $41.55 |
Enterprise Value | $138.23B | $12.30B |
Dividend Yield | 1.01% | — |
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today and near its 52-week high, with a bullish technical outlook from moving averages and strong momentum. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $17.73 surpassing the $14.27 forecast. Valuation ratios appear attractive with a P/E of 13.79 and P/S of 0.77, while profitability metrics like a 47.9% ROE highlight efficient capital use. Recent news emphasizes refinery investments and benefits from geopolitical energy risks.
The outlook for MPC is positive, driven by robust earnings performance, favorable refining margins, and strong analyst support with 26 buy ratings. Key opportunities include high-return projects and cash flow growth, with 2026 net income projected at $8.6B. Risks involve exposure to oil price volatility, cyclical demand, and rising debt-to-asset ratios, which increased to 42.59% in 2025. Investors should weigh solid fundamentals against sector-specific headwinds.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Trailing returns across standard periods
Latest headlines on both assets
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →